Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for<i>Helicobacter pylori</i>eradication: how should rifabutin be managed in rescue regimens?

Losurdo, Giuseppe; Iannone, Andrea; Giorgio, Floriana; Principi, Mariabeatrice; Leo, Alfredo Di; Ierardi, Enzo

doi:10.1177/2050640615623697

Cited by 6 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Losurdo et al 1 raised concerns regarding the accuracy of the eradication rates we reported (83.3% in the 10‐day group and 94.1% in the 14‐day group with intention to treat) because recent studies show lower success rates (60%–80%) in relation to drug dose and treatment duration. There are few reports of rifabutin‐containing regimen from Asia, while most of the reports are from Europe 3 .…”

mentioning

confidence: 82%

“…We appreciate the interest of Losurdo et al 1 in our paper entitled ''Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.'' 2 We agree with them in terms of the importance of confirming tuberculosis status before starting rifabutin therapy, including the regimen, and the assurance of empirical rescue regimens especially in third-or fourth-line treatment.…”

mentioning

confidence: 99%

“…We appreciate the interest of Losurdo et al 1 in our paper entitled “Rifabutin‐based 10‐day and 14‐day triple therapy as a third‐line and fourth‐line regimen for Helicobacter pylori eradication: A pilot study.” 2 …”

mentioning

confidence: 99%

“…Although Losurdo et al. 1 described rifabutin 150 mg b.i.d. as low dose in their quadruple therapy, the daily dose was the same as that in our clinical trial (300 mg q.d.).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Reply to letter to the editor: “The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world”

Mori

Suzuki

2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

mentioning

confidence: 82%

mentioning

confidence: 99%

mentioning

confidence: 99%

“…Although Losurdo et al. 1 described rifabutin 150 mg b.i.d. as low dose in their quadruple therapy, the daily dose was the same as that in our clinical trial (300 mg q.d.).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Reply to letter to the editor: “The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world”

Mori

Suzuki

2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

“…However, rifabutin is associated with serious adverse events, such as myelotoxicity (leukopenia or thrombocytopenia), and the cost is high. Although low phenotypic resistance has been reported, a valid genotypic marker other than mutations in the rpoB gene for rifabutin resistance is not yet available [ 60 ]. All patients with rpoB mutation-positive strains showed successful eradication in a Japanese study, and mycobacterial strains bearing this mutation are often rifabutin-susceptible [ 59 , 61 ].…”

Section: What Is the Current Appropriate Methods To Determine 3rd-lmentioning

confidence: 99%

Current Status of the Third-LineHelicobacter pyloriEradication

Choi

Bang

Lee

et al. 2018

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Antibiotic resistance is growing worldwide, and patients who have failed consecutive 1st- and 2nd-line H. pylori eradication regimens are increasing. Therefore, the role of the bacterial culture with antibiotic susceptibility testing and molecular susceptibility testing is important for avoiding the use of ineffective antibiotics. However, antibiotic susceptibility testing-guided treatment does not necessarily guarantee successful eradication, and there have been mixed results for the effectiveness of a 3rd-line rescue therapy. Therefore, providing patients with pretreatment medication instructions and education is important. It is also crucial to determine the reason of the eradication failure, including host-related factors (poor compliance to eradication regimen, smoking, and cytochrome P450 2C19 genetic polymorphism) or treatment-related factors (inadequate dosage or duration of therapy and gastric acidity), as such factors can be modified for a tailored therapy. Although the indications for H. pylori eradication have widened, patients at a high risk of gastric cancer can gain definitive benefits with a 3rd-line or even 4th-line therapy.

show abstract

Efflux pumps potential drug targets to circumvent drug Resistance – Multi drug efflux pumps of Helicobacter pylori

Raj

Kesavan

Muthusamy

et al. 2021

Materials Today: Proceedings

View full text Add to dashboard Cite

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen forHelicobacter pylorieradication: how should rifabutin be managed in rescue regimens?

Cited by 6 publications

References 13 publications

Reply to letter to the editor: “The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world”

Reply to letter to the editor: “The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world”

Current Status of the Third-LineHelicobacter pyloriEradication

Efflux pumps potential drug targets to circumvent drug Resistance – Multi drug efflux pumps of Helicobacter pylori

Contact Info

Product

Resources

About